Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – X-ray contrast imaging agent
Reexamination Certificate
2007-05-29
2007-05-29
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
X-ray contrast imaging agent
C424S001110, C424S001650, C424S001690, C424S009100
Reexamination Certificate
active
10672763
ABSTRACT:
The invention provides, in a general sense, a new labeling strategy employing99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
REFERENCES:
patent: 4279992 (1981-07-01), Boguslaski et al.
patent: 4418068 (1983-11-01), Jones
patent: 4507466 (1985-03-01), Tomalia et al.
patent: 4558120 (1985-12-01), Tomalia et al.
patent: 4568737 (1986-02-01), Tomalia et al.
patent: 4587329 (1986-05-01), Tomalia et al.
patent: 4631337 (1986-12-01), Tomalia et al.
patent: 4694064 (1987-09-01), Tomalia et al.
patent: 4713975 (1987-12-01), Tomalia et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 4737550 (1988-04-01), Tomalia
patent: 4789542 (1988-12-01), Goodman, Jr. et al.
patent: 4824659 (1989-04-01), Hawthorne
patent: 4857599 (1989-08-01), Tomalia et al.
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4871779 (1989-10-01), Killat et al.
patent: 4925650 (1990-05-01), Nosco et al.
patent: 4965392 (1990-10-01), Fritzberg et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5164294 (1992-11-01), Skold et al.
patent: 5268163 (1993-12-01), Verbruggen
patent: 5279811 (1994-01-01), Bergstein et al.
patent: 5356793 (1994-10-01), Koezuka et al.
patent: 5412072 (1995-05-01), Sakurai et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5517993 (1996-05-01), Unger et al.
patent: 5534241 (1996-07-01), Torchilin et al.
patent: 5605671 (1997-02-01), Lyle et al.
patent: 5620675 (1997-04-01), McBride et al.
patent: 5635382 (1997-06-01), Low et al.
patent: 5635603 (1997-06-01), Hansen et al.
patent: 5643883 (1997-07-01), Marchase et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5688487 (1997-11-01), Linder et al.
patent: 5688488 (1997-11-01), Low et al.
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 5820847 (1998-10-01), Low et al.
patent: 5830431 (1998-11-01), Srinivasan et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5891468 (1999-04-01), Martin et al.
patent: 5908777 (1999-06-01), Lee et al.
patent: 5951964 (1999-09-01), Dean et al.
patent: 5955053 (1999-09-01), Marzilli et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 5986074 (1999-11-01), Marzilli et al.
patent: 6033884 (2000-03-01), Woo et al.
patent: 6054436 (2000-04-01), Crabtree et al.
patent: 6071533 (2000-06-01), Papahadjopoulos et al.
patent: 6083741 (2000-07-01), Hart et al.
patent: 6113946 (2000-09-01), Szoka, Jr. et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6251866 (2001-06-01), Prakash et al.
patent: 6262107 (2001-07-01), Li et al.
patent: 2001/0034363 (2001-10-01), Li et al.
patent: 2001/0041189 (2001-11-01), Xu
patent: WO 91/16076 (1991-10-01), None
patent: WO 95/28966 (1995-11-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 99/39748 (1999-08-01), None
patent: WO 99/49901 (1999-10-01), None
patent: WO 99/61512 (1999-12-01), None
patent: WO 00/53233 (2000-09-01), None
patent: WO 00/61788 (2000-10-01), None
patent: WO 01/80906 (2001-11-01), None
patent: WO 01/91807 (2001-12-01), None
Anderson et al (The Journal of Nuclear Medicine, May 1995, vol. 36, No. 5, pp. 850-858).
Anderson et al (The Journal of Nuclear Medicine, 1992, vol. 33, No. 9, pp. 1685-1691).
Auzeloux et al (Jun. 1999), Journal of Labelled Compounds and Radiopharmaceuiticals, vol. 42, pp. 567-579.
Kung et al (1985), J. Med. Chem., vol. 28, pp. 1280-1284.
Andersen et al (Feb. 1995), Nucl. Med. Biol., vol. 22, No. 2, pp. 165-173.
Sun et al, J. Med. Chem., 1996, vol. 39., pp. 458-470.
Abrams et al., “Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats,”J. Nucl. Med., 31:2022-2028, 1990.
Alper et al., “Assessment of renal functional changes following transurethral prostatectomy suing tc-99m ethylenedicysteine,”J. Nuclear Med., 37:289P, Abstract No. 1292, 1996.
Anderson et al., “N,N′-ethylene-di-l-cysteine (ec) complexes of ga(III) and In (III): molecular modeling, thermodynamic stability and in vivo studies,”Nucl. Med. Biol., 22:165-173, 1995.
Anderson et al., “Radiometal-labeled agents (non-technetium) for diagnostic imaging,”Chem. Rev., 99:2219-2234, 1999.
Antony, “Folate receptors,”Ann. Rev., 16:501-521, 1996.
Aoi et al., “Globular carbohydrate macromolecule ‘sugar balls’3. ‘radical-growth polymerization’ of sugar-substituted α-amino acid N-carboxyanhydrides (glycoNCAx) with a dendritic initiator,”Tetrahedron, Elsevier Science Publishers, 53(45):15415-15427, 1997.
Baidoo and Lever, “Evaluation of diaminedithiol-based bifunctional chelate for labeling small molecules with99mTc,”Technetitum and Rhenium in Chemistry and Nuclear Medicine, 1990.
Baidoo et al., “Synthesis of a new diaminedithiol bifunctional chelate for the preparation of nuetral technetium complexes,”J. Nuclear Med., 31:806, Abstract No. 414, 1990.
Bajorin et al.,Proc. Annu. Meet. Am. Soc. Clin. Oncol., 7:250, A967, 1988.
Bakker et al., “Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity and in vivo application in animals,”J. Nucl. Med., 31:1501-1509, 1990.
Bar-Sever et al., “Comparison of living related donor and recipient renograms in predicting the early postransplantation course,”J. Nuclear Med., 37:292P, Abstract No. 1305, 1996.
Baselga et al., “Phase I studies of anti-epidermal growth factor receptor cheimeric antibody C225 alone and in combination with cisplatin,”J. Clinical Oncology, 18(4):904-914, 2000.
Baselga et al., “Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paciltazel and doxorubicin against HER2
ew overexpressing human breast cancer xenografts,”Cancer Research, 58:2825-2831, 1998.
Benns et al., “Tailoring new gene delivery designs for specific targets,”Journal of Drug Targeting, 8(1), Database Medline on STN International, Accession No. 2000222278, 2 pages, 2000.
Blackenberg et al., “Apoptosis: the importance of nuclear medicine,”Nucl. Med. Comm., 21:241-250, 2000.
Blackenberg et al., “In vivo detection and imaging of phosphatidylserine expression during programmed cell death,”Proc. Natl. Acad. Sci., USA, 95:6349-6354, 1998.
Blair et al., “Linkage of cytotoxin agents to immunoglobulins,”Journal of Immunological Methods, 59:129-143, 1983.
Blakenberg et al., “Imaging of apoptosis (programmed cell death) with99mTc annexin V.,”J. Nucl. Med., 40:184-191, 1999.
Block, “Poly(g-benzyl-L-glutamate) and other glutamic acid containing polymers,” Gordon and Breach Science Publishers, New York, 11-31, 1983.
Blondeau et al., “Dimerization of an intermediate during the sodium in liquid ammonia reduction of L-thiazolidine-4-carboxylic acid,”Can J. Chem, 45:49-52, 1967.
Bohdiewicz et al., “Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging,”J. Nuclear Medicine Technology, 26(3):155-163, 1998.
Brechbiel et al., “Synthesis of 1 (P-isothiocyanatobenzyl) derivitatives of DTPA and EDTA: antibody labeling and tumor-imaging studies,”Inorg. Chem., 25:2772-2781, 1986.
Brogi et al., “Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression,”J. Clin. Invest., 97(2):469-476, 1996.
Brokx et al., “Designing peptide-based scaffolds as drug delivery vehicles,”Science, 78(1-3):115-123, 2002.
Budihardjo et al., ȁ
Kim E. Edmund
Liu Chun W.
Yang David J.
Yu Dong-Fang
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Jones Dameron L.
LandOfFree
Ethylenedicysteine (EC)-drug conjugates, compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ethylenedicysteine (EC)-drug conjugates, compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ethylenedicysteine (EC)-drug conjugates, compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822369